Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
HLA Genetic Risk Burden in Multiple Sclerosis-Reply.
Selective depletion of CD11c(+) CD11b(+) dendritic cells partially abrogates tolerogenic effects of intravenous MOG in murine EAE.
Neurologic Diseases in Special Care Patients.
Neurologic indications for therapeutic plasma exchange: 2011 update.
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO.
Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease.
The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis.
Optic neuritis and TNF antagonists in IBD.
Mitochondrial STAT3 is negatively regulated by SOCS3 and upregulated after spinal cord injury.
Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.
The Role of Galectin-3: From Oligodendroglial Differentiation and Myelination to Demyelination and Remyelination Processes in a Cuprizone-Induced Demyelination Model.
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities.
Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.
Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development.
The best basic science paper on multiple sclerosis in 2012: Commentary.
A Clinical Decision Support System with an Integrated EMR for Diagnosis of Peripheral Neuropathy.
In vivo amyloid aggregation kinetics tracked by time-lapse confocal microscopy in real-time.
Opposing Roles of Interferon-Gamma on Cells of the Central Nervous System in Autoimmune Neuroinflammation.
HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence.
A Microsoft Kinect-Based Point-of-Care Gait Assessment Framework for Multiple Sclerosis Patients.
Epidemiology of Major Neurodegenerative Diseases in Women: Contribution of the Nurses' Health Study.
Genetics of rat neuroinflammation.
Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine.
Environmental factors in autoimmune diseases and their role in multiple sclerosis.
Pages
« first
‹ previous
…
741
742
743
744
745
746
747
748
749
…
next ›
last »